Precision Neuroscience Valuation, Funding & Investors

Precision Neuroscience is valued at $543M as of November 2024.

Last Precision Neuroscience valuation

$543M

Series C · Nov 2024

Last Precision Neuroscience funding round

$126M

Series C · Nov 2024

Cumulative funding Precision Neuroscience raised

$179M

across 3 funding rounds

Key investors in Precision Neuroscience

  • Alumni Ventures
  • B Capital
  • Steadview Capital
  • Forepont Capital Partners
  • Draper Associates
  • Mubadala

Precision Neuroscience Overview

About Precision Neuroscience

Precision Neuroscience is a New York-headquartered developer of brain-computer interface technology. Founded in 2021, it creates minimally invasive, removable cortical implants capable of high-resolution neural recording to treat neurological disorders affecting billions globally.


Founded

2021

HQ

United StatesNew York City, NY

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Valuation

$543M (Nov 2024)

Precision Neuroscience Valuation

Precision Neuroscience is currently valued at $543M, based on its Series C in November 2024.

The $126M round was led by Alumni Ventures and General Equity Holdings.

Precision Neuroscience valuation by funding round

Precision Neuroscience valuation by funding round
DateStageValuation
Nov 2024Series C$543M

Precision Neuroscience Funding History

Precision Neuroscience has raised a total of $179M across 3 funding rounds.

Precision Neuroscience's first fundraising round was a $12M Series A in May 2021. The most recent completed round was a $126M Series C in November 2024.

Precision Neuroscience funding rounds

Precision Neuroscience funding rounds
DateStageInvestorsRaisedValuationDeal Summary
Nov 2024Series CAlumni Ventures (lead); General Equity Holdings (lead)$126M$543MPrecision Neuroscience develops minimally invasive, removable brain-computer interfaces (BCI) designed to treat neurological illnesses by enabling paralyzed individuals to control computers with thoughts, positioning itself as a leader in the BCI industry amid growing investor interest. The company announced a $102 million Series C funding round on December 16, 2024, led by General Equity Holdings, with participation from B Capital, Duquesne Family Office, and Steadview Capital, bringing total funding to $155 million. Funds will support clinical research and accelerate development of its AI-powered brain implant. Forge Global lists this Series C at a $542.69 million post-money valuation, with total funding reaching $182.65 million across rounds. Earlier, Precision raised a $41 million Series B led by ForgePoint Capital (noted as Forepont in some sources), with investors including B Capital, Mubadala Capital, Draper Associates, re.Mind Capital, Steadview Capital, and Alumni Ventures. No details found for a $126 million round involving Alumni Ventures and General Equity Holdings around June 11, 2024; investor lists confirm Alumni Ventures in prior rounds but not this specific combination or date. The BCI market is projected to reach $400 billion in the U.S., per Morgan Stanley, with Precision advancing clinical trials and hardware-software innovations.
Jan 2023Series BForepont Capital Partners (lead); Steadview Capital; Alumni Ventures; Mubadala; B Capital; Draper Associates; re.Mind Capital$41M-Precision Neuroscience is a New York City-based brain-computer interface (BCI) company developing high-resolution, minimally invasive, and reversible implants for treating neurological conditions. The company was founded in 2021 by Chief Science Officer Dr. Ben Rapoport, a neurosurgeon and former Neuralink co-founder, and CEO Michael Mager. The company's flagship technology, the Layer 7 Cortical Interface, is an ultra-thin flexible implant approximately one-fifth the thickness of a human hair that conforms to the brain surface without penetrating tissue. The implantation uses a minimally invasive micro-slit surgical approach requiring incisions of only 400 microns in width, differentiating it from more invasive alternatives like Neuralink's craniotomy-based approach. In January 2023, Precision Neuroscience closed a $41 million Series B funding round led by Forepont Capital Partners, with participation from Mubadala Capital, Draper Associates, Alumni Ventures, re.Mind Capital, and existing investors Steadview Capital and B Capital Group. This brought the company's total funding to $53 million within less than two years of founding. The Series B financing was intended to support hiring of specialized talent, advance product development, and facilitate FDA regulatory review, which was expected in the coming months. The company reported positive results from a pilot study of its Layer 7 Cortical Interface in September 2023, demonstrating the technology's capability for high-resolution mapping of brain activity and stimulation. By October 2023, the company raised an additional $93 million in a Series C round, bringing total funding to approximately $146 million at a reported post-money valuation of around $500 million. By March 2026, the company's total funding reached $182.6 million according to secondary sources.
May 2021Series AB Capital (lead); Steadview Capital (lead); Forepont Capital Partners$12M-Precision Neuroscience raised $12 million in a Series A financing round on May 25, 2021, led by Steadview Capital and B Capital Group's Ascent Team, along with Forepont Capital Partners. The company develops a platform for next-generation brain-computer interface technology focused on minimally invasive device delivery to address underserved medical needs like paralysis and neurological disorders. The funding supports development of an integrated system of electronics, software, and neural implants, building on nearly two decades of team experience in brain-computer interfaces. Precision Neuroscience aims to deliver life-changing technology to millions of patients worldwide, transforming interactions with machines and addressing large patient populations underserved by current medical technology. The company has offices in New York, California, and Massachusetts. Subsequent rounds include $41 million in February 2023 and additional funding in 2024-2025, bringing total funding over $155 million since 2021.

Who has invested in Precision Neuroscience?

8 investors have backed Precision Neuroscience across its funding rounds, including Alumni Ventures, B Capital, Steadview Capital, Forepont Capital Partners, Draper Associates and Mubadala.

Lead investors include Alumni Ventures, General Equity Holdings, Forepont Capital Partners, B Capital and Steadview Capital.


Precision Neuroscience Investors

Investors in Precision Neuroscience by funding rounds participated
InvestorHQRoundsRoleFirst check
Forepont Capital PartnersUnited StatesNew York City, NY2LeadMay 2021
Steadview CapitalUnited KingdomLondon2LeadMay 2021
Alumni VenturesUnited StatesUnited States2LeadJan 2023
B CapitalUnited StatesLos Angeles, CA2LeadMay 2021
MubadalaUAEAbu Dhabi1ParticipantJan 2023
General Equity HoldingsUnited StatesNew York City, NY1LeadNov 2024

This data is available for Pro users. Sign up to see all 8 Precision Neuroscience investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Precision Neuroscience Competitors

Precision Neuroscience competitors include listed companies like Delcath Systems and Sunmax Biotechnology, and private ones like ZD Medtech, Cornerstone Robotics, Petmate and AutoAI.

Public and private companies comparable to Precision Neuroscience
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
ZD MedtechChinaShanghaiPrivate--$900M-
Cornerstone RoboticsHong KongHong KongPrivate--$1B-
PetmateUnited StatesSan Francisco, CAPrivate--$420M-
Delcath SystemsUnited StatesUnited StatesPublicly listed$85M$939K$564M4.7x
AutoAIChinaBeijingPrivate--$570M-
Sunmax BiotechnologyTaiwanTaiwanPublicly listed$64M$35M$670M-

Precision Neuroscience Public Comps

Precision Neuroscience is still privately-owned, but its public comps include BrainsWay, Ocumension, SD Biosensor, Cerus, Delcath Systems, OrthoPediatrics, Tactile Medical, IBA Group, Kamada and The Beauty Tech Group.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
BrainsWay$52M$7M9.3x7.6x71.7x41.7x
Ocumension$120M($3M)4.1x-(178.3x)-
SD Biosensor$517M($509M)0.8x-(0.8x)-
Cerus$206M($5M)2.7x2.2x(112.8x)42.1x
Delcath Systems$85M$939K5.5x4.7x501.0x28.4x
OrthoPediatrics$236M($12M)2.6x2.4x(51.6x)28.2x
Tactile Medical$330M$36M1.3x1.2x12.3x9.1x
IBA Group$714M$40M0.8x0.8x14.8x10.5x

This data is available for Pro users. Sign up to see all Precision Neuroscience competitors and their valuation data.

Start Free Trial

Common questions about Precision Neuroscience

When was Precision Neuroscience founded?Precision Neuroscience was founded in 2021.
Where is Precision Neuroscience headquartered?Precision Neuroscience is headquartered in New York City, NY, United States.
Is Precision Neuroscience publicly listed?No, Precision Neuroscience is a private, VC-backed company.
What is Precision Neuroscience's valuation?Precision Neuroscience was last valued at $543M in its Series C in November 2024.
How much funding has Precision Neuroscience raised?Precision Neuroscience has raised $179M across 3 funding rounds.
What was Precision Neuroscience's last funding round?Precision Neuroscience's last funding round was a $126M Series C in November 2024, led by Alumni Ventures and General Equity Holdings.
Who are Precision Neuroscience's investors?Precision Neuroscience's investors include Forepont Capital Partners, Steadview Capital, Alumni Ventures, B Capital, Mubadala, General Equity Holdings, Draper Associates and re.Mind Capital.
Which companies are comparable to Precision Neuroscience?Companies comparable to Precision Neuroscience include ZD Medtech, Cornerstone Robotics, Petmate, Delcath Systems, AutoAI and Sunmax Biotechnology.

See companies similar to Precision Neuroscience

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial